Introduction
Multiple myeloma is a fatal plasma cell malignancy characterized by the accumulation of latent plasma cells in the bone marrow. 1 Numerous investigators have examined the frequency of ras mutations in multiple myeloma, and have reported a correlation between activating ras mutations and disease progression. [2] [3] [4] Furthermore, Rowley et al 5 demonstrated that ANBL6 myeloma cells transfected with activated N-or K-Ras were more resistant to apoptosis induced by dexamethasone, doxorubicin, and melphalan, suggesting a role for Ras mutations in resistance to chemotherapeutic drugs. 5 Following initial response to therapy, patients with multiple myeloma invariably relapse and are refractory to additional treatment regimens. Thus, myeloma has long served as a model system for investigation of the drug-resistant phenotype. These model systems have led to the characterization of several mechanisms of resistance, including overexpression of the anti-apoptotic protein, Bcl-x L , 6 induced expression of the ATP dependent efflux pump P-glycoprotein, The Ras oncoprotein is a small G-protein signal tranducer that requires a prenyl lipid modification and membrane association for signal transduction activity. 9, 10 Two enzymes, farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I), catalyze this prenyl posttranslational modification by transferring farnesyl or geranylgeranyl to the cysteine of the carboxyl terminal CAAX (C = cysteine, A = aliphatic, X = any amino acid). H-, N-, and K-Ras are all farnesylated. When FTase is inhibited, K-Ras, but not N-Ras or H-Ras, becomes geranylgeranylated. 11 Because prenylation is required for the oncogenic activity of Ras, we, and others designed FTase and GGTase I inhibitors as potential anticancer drugs. 12 To date, the majority of studies using prenylation inhibitors have focused on solid tumors, including lung, bladder, breast, and colon carcinomas. 11, [13] [14] [15] In this study, we examined the activity of prenylation inhibitors in myeloma cell lines with different Ras mutation status, using the CAAX peptidomimetics FTI-277 16 and GGTI-2166. 17 These inhibitors are structural analogues based on the tertiary structure of the CAAX tetrapeptide. 12 Cytotoxicity and growth inhibition were examined for correlation with inhibition of Ras protein processing. In addition, myeloma cell lines with well-characterized mechanisms of drug resistance were analyzed for response to farnesyltransferase inhibitors (FTI). No cross-resistance to FTI was identified in myeloma cells selected for resistance to doxorubicin or melphalan, nor did forced constitutive overexpression of Bcl-x L confer resistance to FTI. These studies provide support for further pre-clinical and clinical trials with prenylation inhibitors in drug-resistant myeloma.
Materials and methods

Cell lines and drugs
The RPMI 8226, U266, and H929 multiple myeloma cell lines were maintained in RPMI medium (CellGro, MediaTech, Herndon, VA, USA) supplemented with 5% or 10% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA, USA), 1% penicillin/streptomycin (P/S), and 100 mM L-glutamine (Gemini Bio-Products, Calabasas, CA, USA). The H929 cell line was also supplemented with 0.05 M 2-mercaptoethanol (Sigma, St Louis, MO, USA). U266 cells transfected with Bclx L were cloned and selected for high (U266/Bcl-xl) or low (U266/Neo) Bcl-x L protein expression and have been previously described. 18 The drug-resistant cell lines, 8226/Dox40, 7 8226/Dox1V, 8 and 8226/LR5 19 have all been previously described. The farnesyltransferase inhibitor (FTI)-277 16 and geranylgeranyltransferase inhibitor (GGTI)-2166 17 were initially dissolved in 10 mM dithiothreitol in dimethyl sulfoxide (DTT/DMSO) and diluted to the appropriate concentrations with RPMI complete medium. 
MTT cytotoxicity assay
Soft agar clonogenic assay
Cells were seeded at densities established for optimal cloning efficiency (range: 24 000-30 000 cells per well) and grown in 0.3% agar (Difco, Detroit, MI, USA) layered over 0.6% agar. FTI-277 or vehicle control (10 mM DTT/DMSO) was included in the 0.3% agar layer of cells. Approximately 2-3 weeks after plating, colonies were stained with 1 mg/ml MTT and counted.
Ras processing assay
Cells were treated with FTI-277, GGTI-2166, or combinations thereof for 48 h. Following drug exposure, cells were washed in PBS and lysed in a buffer containing 30 mM Hepes, pH 7.5, 10 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM MgCl 2 , 1 mM EGTA, 25 mM NaF, 25 g/ml leupeptin, 2 mM phenylmethylsulfonylfluoride (PMSF), 2 mM sodium orthovanadate, 10 g/ml soybean trypsin inhibitor, and 10 g/ml aprotinin. The lysates were cleared and total protein was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein (50 g) were separated on 12.5% SDS-PAGE and transferred to PVDF membrane (BioRad). Membranes were probed with polyclonal antisera specific for N-or K-Ras (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-x L (Pharmingen, San Diego, CA, USA), or monoclonal antiserum specific for ␤-actin (Sigma), followed by detection with chemiluminescence (Roche, Indianapolis, IN, USA).
Apoptosis assays
Cells were treated with FTI-277 and/or GGTI-2166 for 48 h continuously, followed by Annexin V-FITC staining according to the manufacturer's protocol (BioVision, Mountain View, CA, USA). In experiments that included Chloromethyl-X-Rosamine (CMXRos) staining for mitochondrial perturbation, cells were incubated with 200 nM CMXRos for 30 min prior to collection (Molecular Probes, Eugene, OR, USA). CMXRos is a fluorescent dye that is retained in the mitochondria by the mitochondrial membrane potential (MMP). Loss of MMP is detected by reduced fluorescence intensity in apoptotic cells. Flow cytometry acquisition was done on a FACSCalibur and analyzed with CellQuest software (Becton Dickinson, Carpinteria, CA, USA).
Statistical analysis
IC 50 values were calculated and 95% confidence intervals were estimated using a simple linear regression analysis following logistic transformation of the response variable where applicable. Differences across cell lines or doses were tested using either the Student's t-test or Wilcoxon rank sum test. Differences in the mean of the transformed responses were determined by 95% confidence intervals. In the combination FTI-277/GGTI-2166 study, a linear regression analysis was used to test for synergism and additivity across dose levels.
Results
Myeloma cells with a N-Ras mutation are highly sensitive to FTI-277
We used MTT and clonogenic assays to determine the sensitivity of myeloma cells to growth inhibition by FTI-277. The MTT assay measures the metabolic activity of cells, while the soft agar clonogenic assay assesses the ability of cells to divide and form colonies in an anchorage-independent fashion. H929 cells, which express activated N-Ras, were found to be significantly more sensitive to growth inhibition by FTI-277 than either U266 cells, which express wild-type Ras, or 8226 cells, which express activated K-Ras ( Figure 1a 
. Neither mutant N-nor K-ras containing cells were significantly different in sensitivity to FTI-277 compared to the wild-type ras U266 cells. Because prenylation inhibitors are generally considered to be cytostatic agents, we also examined the ability of FTI-277 to induce apoptosis in myeloma cells. Myeloma cells were treated with FTI-277 for 48 h, followed by staining with Annexin V-FITC and flow cytometry analysis. In correlation with the growth inhibition assays, a dose-dependent response was demonstrated, with greatest cell death in the N-Ras mutant H929 cells, followed by the wildtype U266 cells. Similar to the growth inhibition and clonogenic analysis, the K-ras mutant 8226 cell line was found to be the least sensitive to FTI cytotoxicity (Figure 1c ). These data are also compatible with previous reports, in which tumor cells of epithelial origin with activated K-Ras were shown to be less responsive to FTI treatment compared to cells with activated N-Ras or wild-type Ras.
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Inhibition of Ras processing and relationship to FTIinduced apoptosis
To determine if there was a correlation between inhibition of Ras processing and either growth inhibition or apoptosis, we examined the ability of FTI-277 to block Ras prenylation in the myeloma cell lines. Inhibition of lipid modification of the p21 Ras protein alters the protein mobility on SDS-PAGE, resulting in a shift to a higher apparent molecular weight on Western blots and allowing detection of intracellular drug activity. Although FTI-277 demonstrates greater toxicity in the H929 cell line, inhibition of N-Ras processing is more effective in the U266 cells compared to H929 cells even when treated with doses as low as 1.25 M FTI-277 ( Figure 2 ).
Leukemia
Additionally, N-Ras processing in U266 cells is inhibited at much lower doses (range 1.25-10 M FTI-277) than that required for induction of apoptosis (15-30 M FTI-277), suggesting that the mechanism by which FTI-277 induces apoptosis in U266 most likely does not involve inhibition of the prenylation and function of N-Ras.
Processing of K-Ras in the 8226 cells was completely unaffected by any dose of FTI-277 up to 30 M following 48 h treatment. Because K-Ras becomes geranylgeranylated when FTase is inhibited, 11, 22 we also examined K-Ras prenylation following exposure to the geranylgeranyltransferase inhibitor, GGTI-2166, either alone or in combination with FTI-277. No effect was seen with either FTI-277 or GGTI-2166 alone (Figure 2c ). When 8226 cells were treated simultaneously with FTI-277 and GGTI-2166 for 48 h, inhibition of K-Ras processing occurs in a dose-dependent manner. Maximal response for inhibiting K-Ras processing occurred at 5 M GGTI-2166 in combination with 10 M FTI-277 (Figure 2d) .
Co-treatment of the 8226 cell line with FTI-277 and GGTI-2166 also demonstrated an enhanced apoptotic response above the levels for each drug alone. 8226 cells treated with 30 M FTI-277 alone induced approximately 12% drug-specific apoptosis, while GGTI-2166 treatment alone was completely ineffective in these cells. However, the combination of 10 M GGTI-2166 with FTI-277 increased the cell death two-fold compared to FTI-277 alone in both MTT growth inhibition and Annexin V apoptosis assays (Figure 2 ). Statistical analysis using linear regression with integrated and reduced models demonstrated that growth inhibition and apoptosis following co-treatment with FTI-277 and GGTI-2166 occurs in an additive manner. These data are compatible with previous studies demonstrating that inhibition of farnesyl transferase is insufficient to affect K-ras processing, and concomitant inhibition of geranylgeranyl transferase is required. Furthermore, inhibition of N-Ras processing in H929 and U266 cells occurs at doses well below those necessary to cause growth inhibition and apoptosis, while inhibition of K-Ras processing and significant apoptosis in 8226 cells requires co-treatment with FTI-277 and GGTI-2166. 
Bcl-x L and classical mechanisms of drug resistance are not determinants of resistance to FTI-277
The anti-apoptotic protein Bcl-x L is a known determinant of drug resistance in multiple myeloma and has previously been shown to protect myeloma cells from cytotoxic drugs including doxorubicin, melphalan, mitoxantrone, and VP-16. 18 We explored the ability of FTI-277 to induce apoptosis in myeloma cells overexpressing Bcl-x L . Using U266 cells engineered to constitutively overexpress Bcl-x L (U266/Bcl-xl), we compared the cytotoxic activity of FTI-277 in U266 cells expressing low basal levels of Bcl-x L (U266 and U266/Neo) to those overexpressing Bcl-x L (Figure 3a and b) . Using both MTT cytotoxicity and CMXRos/Annexin V apoptosis assays, no significant difference was found in the response to FTI-277 between the cells expressing low levels of Bcl-x L and those with high constitutive expression. Although we are not aware of any evidence suggesting that farnesyl transferase inhibitors directly affect the activity of BCL-family members, we cannot rule out that possibility based on these studies. Bcl-x L has been shown to prevent cell death by preventing the release of cytochrome c and mitochondrial perturbation. 23 Equal sensitivity of cells expressing varying levels of Bcl-x L indicates that apoptosis induced by the FTIs in myeloma cells occurs through a mitochondrial-independent mechanism. Furthermore, the observation that Bcl-x L does not confer resistance to prenylation inhibitors supports the use of these agents in patients with drug-resistant disease.
Patients with multiple myeloma frequently relapse with multi-drug resistant disease, and myeloma cells selected in vitro for resistance to chemotherapeutic drugs provide a model for examining mechanisms of acquired drug resistance. We utilized cells selected for resistance to doxorubicin, in the presence 8 or absence 7 of the calcium channel blocker, verapamil, and cells selected for resistance to melphalan 19 for cross-resistance to FTI-277. No significant differences were found in the response of the parental cells, 8226/S, as compared to the drug-resistant variants, 8226/Dox40, 8226/Dox1V, or 8226/LR5 (Figure 4) . The 8226/Dox40 cell line has been shown to overexpress the ATP-dependent efflux pump, P-glycoprotein, and is approximately 180-fold resistant to doxorubicin. Additionally, this cell line demonstrates crossresistance to mitoxantrone, etoposide, and vincristine. 7 However, no cross-resistance to FTI-277 was demonstrated, indi- 
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cating that the prenylation inhibitor is not a substrate for Pglycoprotein efflux. Additionally, 8226 drug-resistant cells with other mechanisms of drug resistance, such as altered topoisomerase II activity in the 8226/Dox1V cell line, and elevated levels of intracellular glutathione in the 8226/LR5 cell line, are also not significantly more resistant to treatment with FTI-277 compared to parental cells. These data support the potential utility of FTI inhibitors in relapsed myeloma
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Figure 4
Drug-resistant myeloma cells are not cross-resistant to FTI-277. 8226/S, 8226/Dox40, 8226/Dox1V, and 8226/LR5 were treated with FTI-277 continuously for 96 h and assayed using the MTT cytotoxicity assay. IC 50 s were calculated and 95% confidence intervals were estimated by linear regression of percent survival vs log drug concentration . The IC 50 estimates were calculated from three independent experiments done in quadruplicate. The table summarizes the IC 50 s and 95% confidence intervals for the myeloma cell lines.
patients, either as single agents, or in combination with standard chemotherapeutic drugs.
Discussion
Ras mutations are among the most common oncogenic mutations identified in many malignant diseases, including Clinical trials with FTIs have demonstrated a therapeutic response in leukemia patients, even though Ras mutation status was not a determinant for clinical response. 20, 24 Similarly, preclinical studies using solid tumor xenografts have not supported a correlation of response with Ras mutation status. 20, 21 Thus, the biologic basis for FTI activity in tumor cells is yet to be fully defined.
In this study we examined the cytotoxic activity and inhibition of Ras processing in three myeloma cell lines with differing Ras mutation status. The U266 cell line, which expresses wild-type Ras, is the most sensitive to inhibition of Ras processing, however, these cells are not sensitive to FTImediated cytotoxicity. The H929 cell line, which expresses mutant N-ras, demonstrates an intermediate sensitivity to FTI-277-induced inhibition of N-Ras processing, but is the most sensitive to growth inhibition and apoptosis. In all assays, the 8226 cell line containing a K-ras mutation is the most resistant to the cytotoxic effects of FTI. Similar to previous studies in epithelial carcinomas, K-Ras processing could only be inhibited with a combination of FTI and GGTI in 8226 cells. In a study by Lerner et al, 11 pancreatic, bladder, and pulmonary tumor cells also demonstrated resistance to inhibition of KRas processing when treated with FTI-277 or GGTI-298 alone. Furthermore, inhibition of K-Ras processing in these cell lines did not correlate with growth inhibition as measured by soft agar clonogenic assays. In contrast, in this study the most sensitive cell line is the one with N-Ras mutation suggesting that N-Ras mutation status may be a determinant of response. Consistent with this is the fact that the IC 50 for growth inhibition is similar to that of inhibition of N-Ras processing in H929 but not in U266. In U266, inhibition of N-Ras processing (IC 50 = 2 M) does not result in inhibition of growth (see Figure 1) .
Expression of the anti-apoptotic protein Bcl-x L has been shown to contribute to resistance to a broad range of chemotherapeutic agents in myeloma cells. 6, 18 However, the data presented here demonstrate that FTI-277 is effective in myeloma cells in vitro independent of Bcl-x L expression. The U266 myeloma cell line expresses a basal level of Bcl-x L , that confers resistance to both Fas and chemotherapeutic agents. 18, 25 In contrast, H929 myeloma cells express low levels of Bcl-x L and are more sensitive to the cytotoxicity of the FTIs. This observation led us to examine FTI activity in U266 myeloma cells engineered to express very high levels of Bclx L . 25 In these myeloma cell lines, Bcl-x L expression had no effect on the cytotoxicity of the FTI. These data are in contrast to a previous study demonstrating resistance to the farnesyltransferase inhibitor L-739,749 by Bcl-x L overexpression in Rat1 cells. 26 This discrepancy is most likely due to the different cell types and their relative dependence on Bcl-x L for survival.
Classical mechanisms of acquired drug resistance include increased expression of drug efflux proteins such as P-glycoprotein, reduced expression of intracellular drug targets, such as topoisomerase II, 8 and enhanced drug detoxification by glutathione S-transferase. 19 The novel observation that these classical mediators of drug resistance do not confer crossresistance to FTI-277 provides strong rationale for clinical trials of FTI in myeloma patients that are refractory to standard chemotherapeutic agents.
Therapeutic agents with molecular targets provide a unique opportunity to specifically inhibit malignant growth with minimal systemic toxicity. Many of these agents are being extensively investigated as potential combination therapies, and in fact, previous studies using a xenograft model have demonstrated that FTI in combination with cisplatin, taxol, or gemcitabine is more effective than either agent alone. 17 Our data demonstrate that farnesyl transferase inhibitors inhibit growth and induce apoptosis in both drug-sensitive and drug-resistant myeloma cells in vitro. These results support ongoing clinical studies in myeloma patients, and may contribute to the development of a novel treatment for this incurable disease.
